



**ASX/MEDIA RELEASE**

4 November 2004

**BONE MEDICAL SECURES \$250,000 BIF GRANT  
FOR OSTEOPOROSIS CLINICAL TRIAL**

Biopharmaceutical development company Bone Medical Limited (**ASX: BNE**) is pleased to announce that the company has been awarded a \$250,000 grant from the Federal Government's Biotechnology Innovation Fund (BIF), the maximum amount available under the scheme.

The grant was awarded to continue work on Bone Medical's BN003 oral parathyroid hormone (PTH) project. This project aims to develop an improved therapeutic option for the treatment of osteoporosis, a disease that is predicted to increase dramatically as the baby boomers age over the coming years.

Injectable PTH, which has only been marketed internationally for two years, is the only product accepted by the US Food & Drug Administration (FDA) to claim bone building for the treatment of osteoporosis. Bone Medical's BN003 oral PTH uses innovative technologies that are designed to deliver PTH as a capsule or tablet and thereby overcome the burden and potential complications of taking the drug by injection.

Bone Medical's COO John Fitzgerald said the grant would be used to fund a pre-clinical toxicology study and a first-in-human clinical study for BN003 oral PTH.

"The BIF is a competitive, merit-based program and the award of this non-dilutionary funding provides shareholders further independent validation of our technology and represents another milestone achievement for the company," said John Fitzgerald.

"We now have the opportunity to accelerate our development of BN003, a product that could replace injected PTH with orally delivered treatments and expand the market through greater patient acceptance."

"Both of these studies will be conducted in Sydney, reinforcing our business plan and ongoing commitment to Australian science," he said.

Bone Medical's BN003 oral PTH will target a segment of the osteoporosis market which had total world sales exceeding US\$5 billion in 2002 which is projected to be more than US\$11.5 billion by 2006.

-ENDS-

## **About Bone Medical Limited**

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including;

### Osteoporosis

- oral calcitonin BN002
- oral parathyroid hormone BN003
- combination therapy

### Arthritis

- TNF regulators BN006
- bone cell regulators BN005/BN008
- joint protection & collagen tolerance BN007

## **About the Biotechnology Innovation Fund (BIF)**

The Biotechnology Innovation Fund (BIF) is a \$40 million Australian Government scheme which helps biotechnology companies to move their projects beyond research stage and into early commercialisation. BIF helps companies reduce the cost of demonstrating proof-of-concept of their project and may assist them to attract investment.

### **For more information about Bone Medical Limited, please contact:**

Dr Jim Phillips  
Chief Executive Officer  
+33 450734761

John Fitzgerald  
Chief Operating Officer  
+61 (0)419 600 375

Ann M. Nahajski  
Porter Novelli  
+61 8 9386 1233

Or visit:

[www.bonemedical.com](http://www.bonemedical.com)